Agreed...how about an explanation of exactly what preclinical testing is being undertaken at the FDA's request in support of the parkinsons' IND, and the status of that testing. The FDA could learn a thing or two about moving the goal posts from Titan's management, who constantly move goals backwards in time and describe it as "being on track."
On sales, they always defer to Braeburn, but I seem to remember that Titan has the contract with the third party manufacturer of the rods (not Braeburn). So until Braeburn builds its own facility, they should be in a position to know how many rods have been ordered and there is nothing in the license agreement with Braeburn that would prevent them from letting us know. But, I'm not really sure on how the entire supply chain relationship is structured (I could be wrong), which only points to how little they disclose.
I really don't think they've done anything at all on a ROW deal. Sunil bought shares recently, which is notable in that (1) for most public companies, buying or selling of shares is forbidden during the "quiet period" between the end of a quarter and the release of earnings, and (2) we must assume that, in order to comply with federal securities laws, he was not in possession of any material nonpublic information at the time he bought those shares. A ROW deal (or any buyout discussions) would certainly be "material nonpublic information," and so its logical to assume that nothing is happening on that front.
But their proxy statement asking for additional option shares to reward their performance was nicely done....
News 
Market Data 
Discover 
